Official Title
Neurologic Manifestations of COVID 19 in Children
Brief Summary

This is a multicenter, multinational observational cohort study to document neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or suspected COVID 19 (Coronavirus 19 disease, caused by infection with the SARS-CoV-2 (acute respiratory syndrome 2 ) virus. SARS-CoV2 shares significant structural and biological similarities with SARS-CoV including using the ACE-2 receptor as a docking site, a property that confers neurotropism. This study is sponsored and led by members of the Pediatric Neurocritical Care Research Group (PNCRG).

Detailed Description

Early reports of COVID-19 indicate that adults experience a variety of neurological symptoms and diagnoses in approximately 36% of patients, including headaches, seizures, coma, encephalitis, and cerebrovascular events including ischemic stroke, intracranial hemorrhage, and cerebral venous sinus thromboses. In children, recent evidence highlights acute and long-term neurological manifestations due to other viral illnesses including Guillain Barre syndrome and neonatal microcephaly with Zika virus, encephalitis with H1N1 influenza, and acute flaccid paralysis with enterovirus-68. However, COVID-19 reports in children published thus far lack detailed information on the frequency and outcomes of neurological findings.

COVID-19 cases are rapidly rising internationally, with experts forecasting subsequent global surges and continued activity. Thus, it is imperative to accurately document prevalence and outcomes of the neurological aspects of COVID-19 specifically in children. Such data will serve to alert clinicians and families about the possibility that children may present with neurologic rather than "classic" symptoms of COVID-19 who nevertheless would warrant testing, and that neurologic events can occur subsequent to the diagnosis that may impact long-term outcomes (e.g., cognitive, emotional, physical health). The investigators anticipate that improved knowledge about neurologic manifestations in children will bolster personalized treatment and rehabilitation strategies to optimize child outcomes and inform future interventional studies.

Recruiting
COVID
Neurologic Manifestations

Other: Observational study only
No Intervention
Children <18

Eligibility Criteria

Inclusion Criteria:

- Infants, children, and young adults age < 18 years

- Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)

Exclusion Criteria:

- none

Eligibility Gender
All
Eligibility Age
Maximum: 17 Years
Countries
United States
Locations

UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224

Recruiting

Investigator: Ericka L Fink
finkel@ccm.upmc.edu

Contacts

Ericka L Fink, MD
412-692-5164
FinkEL@ccm.upmc.edu

David Maloney, BS
412-692-6829

Ericka L Fink, MD
Principal Investigator
University of Pittsburgh

University of Pittsburgh
University of Utah
Johns Hopkins University
NCT Number
Keywords
Child
neurocritical care
Covid-19
neurologic manifestations
MeSH Terms
Neurologic Manifestations